Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Alzheimer's Disease

Free Subscription Articles published in Lancet Neurol Retrieve available abstracts of 58 articles: HTML format

Single Articles

April 2026
1. MATTSSON-CARLGREN N, Palmqvist S, Horie K, Barthelemy N, et al
   Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study.
   Lancet Neurol. 2026;25:357-367.
   PubMed     Abstract available
   
   
   
2. ASHTON NJ
   Biologically informed blood testing in Alzheimer's disease.
   Lancet Neurol. 2026;25:327-329.
   PubMed    
   
   
   March 2026
3. REIMAN EM, Alexander RC, Langbaum JB, Aisen PS, et al
   A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA.
   Lancet Neurol. 2026;25:268-278.
   PubMed     Abstract available
   
   
   
4. SCHNEIDER L
   When Alzheimer's disease prevention becomes policy: regulatory speed, commercialisation, and risk.
   Lancet Neurol. 2026;25:219-220.
   PubMed    
   
   
   
5. THE LANCET NEUROLOGY
   Stopping Alzheimer's disease before symptoms start.
   Lancet Neurol. 2026;25:213.
   PubMed    
   
   
   February 2026
6. TARIOT PN, Lopera FS, Rios-Romenets S, Sink KM, et al
   Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1(Glu280Ala) mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled tri
   Lancet Neurol. 2026;25:147-159.
   PubMed     Abstract available
   
   
   
7. FORTEA J, Llibre-Guerra J, O'Connor A, Levin J, et al
   Lessons from the Colombian kindred: rethinking Alzheimer's prevention.
   Lancet Neurol. 2026;25:117-119.
   PubMed    
   
   
   January 2026
8. VOSSEL K, Johnson EL, Cretin B, Matsumoto R, et al
   Epileptic activity in Alzheimer's disease: emerging insights and therapeutic implications.
   Lancet Neurol. 2026 Jan 22:S1474-4422(25)00425.
   PubMed     Abstract available
   
   
   
9. DEVINSKY O
   Alzheimer's disease and epileptic activity: uncertainties abound.
   Lancet Neurol. 2026 Jan 22:S1474-4422(25)00496.
   PubMed    
   
   
   
10. MORGAN J
    Takeshi Iwatsubo: a pioneer in Alzheimer's disease research.
    Lancet Neurol. 2026;25:33.
    PubMed    
    
    
    December 2025
11. RABINOVICI GD
    Progress in Alzheimer's disease: The Lancet Series.
    Lancet Neurol. 2025;24:991-992.
    PubMed    
    
    
    
12. SCHOLZ SW, Okubadejo NU, Prakash P, Liddelow SA, et al
    Advances in the genetics and pathology of Lewy body dementia.
    Lancet Neurol. 2025;24:1026-1037.
    PubMed     Abstract available
    
    
    
13. JACK CR JR, Hu M, Wiste HJ, Knopman DS, et al
    Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study.
    Lancet Neurol. 2025;24:1016-1025.
    PubMed     Abstract available
    
    
    November 2025
14. BOON BDC, Piura YD, Moloney CM, Chalk JL, et al
    Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study.
    Lancet Neurol. 2025;24:931-944.
    PubMed     Abstract available
    
    
    
15. IWATSUBO T
    Neuropathology of Alzheimer's disease after anti-amyloid beta antibody treatment.
    Lancet Neurol. 2025;24:897-899.
    PubMed    
    
    
    September 2025
16. RAFII MS, Schlachetzki Z, Barroeta I, Head E, et al
    Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology.
    Lancet Neurol. 2025;24:753-762.
    PubMed     Abstract available
    
    
    
17. THERRIAULT J, Brum WS, Trudel L, Macedo AC, et al
    Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Lancet Neurol. 2025;24:740-752.
    PubMed     Abstract available
    
    
    
18. RYAN NS
    Alzheimer's disease in Down syndrome: progress and promise.
    Lancet Neurol. 2025;24:717-718.
    PubMed    
    
    
    
19. KESHAVAN A, Algeciras-Schimnich A
    Plasma phosphorylated tau for Alzheimer's disease diagnosis.
    Lancet Neurol. 2025;24:715-717.
    PubMed    
    
    
    August 2025
20. LI Y, Llibre-Guerra JJ, Supnet C, Atri A, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease - Authors' reply.
    Lancet Neurol. 2025;24:635-636.
    PubMed    
    
    
    
21. CHENG Y, Zhang Y, Zhang S, Shang H, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease.
    Lancet Neurol. 2025;24:634.
    PubMed    
    
    
    
22. WALSH S, Howard R, Richard E, Milne R, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease.
    Lancet Neurol. 2025;24:634.
    PubMed    
    
    
    July 2025
23. TEUNISSEN C, Duits F
    Plasma biomarkers for diagnosis and prognosis in Down syndrome-related Alzheimer's disease.
    Lancet Neurol. 2025;24:561-562.
    PubMed    
    
    
    June 2025
24. MARINO C, Malotaux V, Giudicessi A, Aguillon D, et al
    Protective genetic variants against Alzheimer's disease.
    Lancet Neurol. 2025;24:524-534.
    PubMed     Abstract available
    
    
    
25. THE LANCET NEUROLOGY
    A genetic framework for Alzheimer's disease prevention.
    Lancet Neurol. 2025;24:471.
    PubMed    
    
    
    May 2025
26. MATAR E, Halliday GM
    Biological effects of pathologies in Lewy body diseases: why timing matters.
    Lancet Neurol. 2025;24:441-455.
    PubMed     Abstract available
    
    
    April 2025
27. BATEMAN RJ, Li Y, McDade EM, Llibre-Guerra JJ, et al
    Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
    Lancet Neurol. 2025;24:316-330.
    PubMed     Abstract available
    
    
    
28. SCHOTT JM
    Amyloid immunotherapy to prevent Alzheimer's disease: the wrong drug at the right time?
    Lancet Neurol. 2025;24:279-281.
    PubMed    
    
    
    February 2025
29. BLANQUIE O, Guizzaro L, Herold R, Haberkamp M, et al
    EU regulatory horizons for Alzheimer's disease.
    Lancet Neurol. 2025;24:96-97.
    PubMed    
    
    
    
30. MASTERS CL
    Should the preclinical stage of Alzheimer's disease be disclosed?
    Lancet Neurol. 2025;24:94-95.
    PubMed    
    
    
    January 2025
31. THE LANCET NEUROLOGY
    Bridging the diagnostic gap in Alzheimer's disease.
    Lancet Neurol. 2025;24:1.
    PubMed    
    
    
    December 2024
32. SCHWORER EK, Zammit MD, Wang J, Handen BL, et al
    Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.
    Lancet Neurol. 2024;23:1214-1224.
    PubMed     Abstract available
    
    
    
33. HUNDAL H
    Frank Longo: taking on Alzheimer's disease.
    Lancet Neurol. 2024;23:1188.
    PubMed    
    
    
    
34. RAFII MS
    The amyloid clock: mapping Alzheimer's disease in Down syndrome.
    Lancet Neurol. 2024;23:1173-1174.
    PubMed    
    
    
    October 2024
35. STIRRUPS R
    Navigating the roads ahead for Alzheimer's disease.
    Lancet Neurol. 2024;23:971.
    PubMed    
    
    
    
36. HYMAN BT
    Amyloid removal and the appearance of brain volume loss.
    Lancet Neurol. 2024;23:957-958.
    PubMed    
    
    
    
37. BELDER CRS, Boche D, Nicoll JAR, Jaunmuktane Z, et al
    Brain volume change following anti-amyloid beta immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy.
    Lancet Neurol. 2024;23:1025-1034.
    PubMed     Abstract available
    
    
    September 2024
38. THE LANCET NEUROLOGY
    The evolving paradigm of Alzheimer's disease diagnosis.
    Lancet Neurol. 2024;23:845.
    PubMed    
    
    
    August 2024
39. OHRY A
    Ezio Giacobini: a leader in Alzheimer's disease research.
    Lancet Neurol. 2024;23:768.
    PubMed    
    
    
    July 2024
40. SCHULTZ SA, Liu L, Schultz AP, Fitzpatrick CD, et al
    gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00236.
    PubMed     Abstract available
    
    
    
41. POTIER MC, Steiner H, Chavez-Gutierrez L
    Amyloid beta, gamma-secretase, and familial Alzheimer's disease.
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00292.
    PubMed    
    
    
    June 2024
42. KAPASI A, Schneider JA
    Speculation on the transmissibility of Alzheimer's disease.
    Lancet Neurol. 2024;23:555-556.
    PubMed    
    
    
    May 2024
43. WISCH JK, McKay NS, Boerwinkle AH, Kennedy J, et al
    Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2024;23:500-510.
    PubMed     Abstract available
    
    
    
44. NORDBERG A
    Insights into the progression of genetic Alzheimer's disease from tau PET.
    Lancet Neurol. 2024;23:453-454.
    PubMed    
    
    
    March 2024
45. FRISONI GB, Festari C, Massa F, Cotta Ramusino M, et al
    European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.
    Lancet Neurol. 2024;23:302-312.
    PubMed     Abstract available
    
    
    
46. THE LANCET NEUROLOGY
    Dementia diagnosis in the anti-amyloid era.
    Lancet Neurol. 2024;23:219.
    PubMed    
    
    
    February 2024
47. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    PubMed     Abstract available
    
    
    
48. REIMAN EM, Cummings JL, Langbaum JB, Mattke S, et al
    A chance to prevent Alzheimer's disease sooner than you think.
    Lancet Neurol. 2024;23:144-145.
    PubMed    
    
    
    
49. BEJANIN A, Villain N
    Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease.
    Lancet Neurol. 2024;23:127-128.
    PubMed    
    
    
    January 2024
50. DELRIEU J, Andrieu S, Vellas B
    Dementia research in 2023: the year of anti-amyloid immunotherapy.
    Lancet Neurol. 2024;23:13-15.
    PubMed    
    
    
    December 2023
51. RANSCOMBE P
    Powerful series profiles rare forms of dementia.
    Lancet Neurol. 2023;22:1112.
    PubMed    
    
    
    November 2023
52. SCHLEPCKOW K, Morenas-Rodriguez E, Hong S, Haass C, et al
    Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease.
    Lancet Neurol. 2023;22:1048-1060.
    PubMed     Abstract available
    
    
    September 2023
53. JAGUST WJ, Teunissen CE, DeCarli C
    The complex pathway between amyloid beta and cognition: implications for therapy.
    Lancet Neurol. 2023;22:847-857.
    PubMed     Abstract available
    
    
    July 2023
54. BELDER CRS, Schott JM, Fox NC
    Preparing for disease-modifying therapies in Alzheimer's disease.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00274.
    PubMed    
    
    
    
55. FRISONI GB
    Complexity is the simple truth about Alzheimer's disease.
    Lancet Neurol. 2023 Jul 13:S1474-4422(23)00176.
    PubMed    
    
    
    June 2023
56. THE LANCET NEUROLOGY
    Treatment for Alzheimer's disease: time to get ready.
    Lancet Neurol. 2023;22:455.
    PubMed    
    
    
    
57. MASON M, Bacioglu M, Vivacqua G, Spillantini MG, et al
    Targeting tau degradation: a viable therapeutic approach?
    Lancet Neurol. 2023;22:462-464.
    PubMed    
    
    
    May 2023
58. LANGWORTH-GREEN C, Patel S, Jaunmuktane Z, Jabbari E, et al
    Chronic effects of inflammation on tauopathies.
    Lancet Neurol. 2023;22:430-442.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum